Innoviva Shares Outstanding 2012-2026 | INVA

Innoviva shares outstanding from 2012 to 2026. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Unlock Macrotrends Premium
40 years of data
Faster, ad-free pages
Unlimited data exports
Full-width charts
Innoviva Annual Shares Outstanding
(Millions of Shares)
2025 85
2024 74
2023 87
2022 95
2021 94
2020 114
2019 113
2018 113
2017 120
2016 123
2015 115
2014 112
2013 102
2012 91
2011 82
Innoviva Quarterly Shares Outstanding
(Millions of Shares)
2026-06-30 73
2026-03-31 85
2025-12-31 85
2025-09-30 85
2025-06-30 84
2025-03-31 63
2024-12-31 74
2024-09-30 63
2024-06-30 63
2024-03-31 85
2023-12-31 87
2023-09-30 86
2023-06-30 65
2023-03-31 90
2022-12-31 95
2022-09-30 96
2022-06-30 96
2022-03-31 94
2021-12-31 94
2021-09-30 82
2021-06-30 101
2021-03-31 114
2020-12-31 114
2020-09-30 114
2020-06-30 114
2020-03-31 114
2019-12-31 113
2019-09-30 113
2019-06-30 113
2019-03-31 113
2018-12-31 113
2018-09-30 113
2018-06-30 113
2018-03-31 114
2017-12-31 120
2017-09-30 120
2017-06-30 120
2017-03-31 120
2016-12-31 123
2016-09-30 122
2016-06-30 124
2016-03-31 113
2015-12-31 115
2015-09-30 116
2015-06-30 115
2015-03-31 115
2014-12-31 112
2014-09-30 113
2014-06-30 111
2014-03-31 110
2013-12-31 102
2013-09-30 106
2013-06-30 98
2013-03-31 96
2012-12-31 96
2012-09-30 95
2012-06-30 89
2012-03-31 92
2011-12-31 82
2011-09-30 82
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $1.506B $0.411B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $1069.485B 36.08
Johnson & Johnson (JNJ) United States $643.925B 24.60
AbbVie (ABBV) United States $464.737B 24.20
Merck (MRK) United States $354.755B 44.79
Roche Holding AG (RHHBY) Switzerland $350.029B 0.00
Novartis AG (NVS) Switzerland $264.508B 15.97
Novo Nordisk (NVO) Denmark $189.896B 10.58
Pfizer (PFE) United States $157.026B 9.03
Sanofi (SNY) France $102.796B 8.65
Bayer (BAYRY) Germany $55.158B 9.81